<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">problendo</journal-id><journal-title-group><journal-title xml:lang="ru">Проблемы Эндокринологии</journal-title><trans-title-group xml:lang="en"><trans-title>Problems of Endocrinology</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0375-9660</issn><issn pub-type="epub">2308-1430</issn><publisher><publisher-name>Endocrinology Research Centre</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14341/probl13574</article-id><article-id custom-type="elpub" pub-id-type="custom">problendo-13574</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>Болезни костной и жировой ткани</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>Bones &amp; Adipose tissues diseases</subject></subj-group></article-categories><title-group><article-title>Влияние дооперационной терапии бисфосфонатами на минеральную плотность костной ткани у пациентов с ПГПТ через год после паратиреоидэктомии</article-title><trans-title-group xml:lang="en"><trans-title>Effect of preoperative bisphosphonate therapy on bone mineral density in patients with primary hyperparathyroidism one year after parathyroidectomy</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9462-8522</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Першина-Милютина</surname><given-names>А. П.</given-names></name><name name-style="western" xml:lang="en"><surname>Pershina-Miliutina</surname><given-names>A. P.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Першина-Милютина Анастасия Павловна </p><p>117036, Москва, ул. Дм. Ульянова, д. 11 </p></bio><bio xml:lang="en"><p>Anastasiia P. Pershina-Miliutina, MD</p><p>11 Dm.Ulyanova street, 117036 Moscow</p></bio><email xlink:type="simple">oa11111998@gmail.com</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-6667-062X</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Еремкина</surname><given-names>А. К.</given-names></name><name name-style="western" xml:lang="en"><surname>Eremkina</surname><given-names>A. K.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Еремкина Анна Константиновна, к.м.н. </p><p>Москва</p></bio><bio xml:lang="en"><p>Anna K. Eremkina, MD, PhD</p><p>Moscow</p></bio><email xlink:type="simple">eremkina.anna@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3118-1401</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ожималов</surname><given-names>И. Д.</given-names></name><name name-style="western" xml:lang="en"><surname>Ozhimalov</surname><given-names>I. D.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ожималов Илья Дмитриевич </p><p>Москва</p></bio><bio xml:lang="en"><p>Ilia D. Ozhimalov</p><p>Moscow</p></bio><email xlink:type="simple">i.ozhimalov@gmail.com</email><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6758-5918</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Хайриева</surname><given-names>А. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Khairieva</surname><given-names>А. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Хайриева Ангелина Владимировна </p><p>Москва</p></bio><bio xml:lang="en"><p>Angelina V. Khairieva, MD</p><p>Moscow</p></bio><email xlink:type="simple">komarito@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0003-2669-9457</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Горбачева</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Gorbacheva</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Горбачева Анна Максимовна </p><p>Москва</p></bio><bio xml:lang="en"><p>Anna M. Gorbacheva, MD</p><p>Moscow</p></bio><email xlink:type="simple">gorbacheva.anna@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0003-3570-9183</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ронжина</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Ronzhina</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Ронжина Светлана Владимировна </p><p>Москва</p></bio><bio xml:lang="en"><p>Svetlana V. Ronzhina</p><p>Moscow</p></bio><email xlink:type="simple">Ronzhinasveta5@gmail.com</email><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-9717-9742</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Мокрышева</surname><given-names>Н. Г.</given-names></name><name name-style="western" xml:lang="en"><surname>Mokrysheva</surname><given-names>N. G.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Мокрышева Наталья Георгиевна, д.м.н., профессор </p><p>Москва</p></bio><bio xml:lang="en"><p>Natalia G. Mokrysheva, MD, PhD, Professor</p><p>Moscow</p></bio><email xlink:type="simple">mokrisheva.natalia@endocrincentr.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>Национальный медицинский исследовательский центр эндокринологии им. академика И.И. Дедова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.I. Dedov Endocrinology Research Centre</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Московский государственный университет им. М.В. Ломоносова</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Lomonosov Moscow State University</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Первый Московский государственный медицинский университет им. И.М. Сеченова (Сеченовский университет)</institution><country>Россия</country></aff><aff xml:lang="en"><institution>I.M. Sechenov First Moscow State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>14</day><month>09</month><year>2025</year></pub-date><volume>71</volume><issue>4</issue><fpage>57</fpage><lpage>70</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Першина-Милютина А.П., Еремкина А.К., Ожималов И.Д., Хайриева А.В., Горбачева А.М., Ронжина С.В., Мокрышева Н.Г., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Першина-Милютина А.П., Еремкина А.К., Ожималов И.Д., Хайриева А.В., Горбачева А.М., Ронжина С.В., Мокрышева Н.Г.</copyright-holder><copyright-holder xml:lang="en">Pershina-Miliutina A.P., Eremkina A.K., Ozhimalov I.D., Khairieva А.V., Gorbacheva A.M., Ronzhina S.V., Mokrysheva N.G.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.probl-endojournals.ru/jour/article/view/13574">https://www.probl-endojournals.ru/jour/article/view/13574</self-uri><abstract><sec><title>ОБОСНОВАНИЕ</title><p>ОБОСНОВАНИЕ. Основным методом лечения первичного гиперпаратиреоза (ПГПТ) является паратиреоидэктомия (ПТЭ); консервативная терапия, включая бисфосфонаты, может применяться для дооперационной коррекции гиперкальциемии, а также улучшения состояния костной ткани среди лиц, у которых операция должна быть отложена или не может быть проведена ввиду высоких периоперационных рисков. Вопрос о влиянии предоперационной терапии бисфосфонатами (БФ) на костную ткань после операции остается открытым.</p></sec><sec><title>ЦЕЛЬ</title><p>ЦЕЛЬ. Изучить влияние дооперационной терапии бисфосфонатами на параметры МПК, оцениваемые при DXA и 3D-DXA, у пациентов с ПГПТ через год после радикальной ПТЭ.</p></sec><sec><title>МАТЕРИАЛЫ И МЕТОДЫ</title><p>МАТЕРИАЛЫ И МЕТОДЫ. Исследование проведено на базе отделения патологии околощитовидных желез и нарушений минерального обмена ФГБУ «НМИЦ эндокринологии» Минздрава России. В исследование включены 50 пациентов (2 мужчины, 48 женщин), разделенные на две группы в зависимости от наличия или отсутствия дооперационной терапии БФ. Использовались методы DXA и 3D-DXA с применением программного обеспечения 3D-Shaper Medical для оценки МПК и микроархитектоники костной ткани. Статистический анализ выполнен с использованием языка R и пакета Statistica v.13.</p></sec><sec><title>РЕЗУЛЬТАТЫ</title><p>РЕЗУЛЬТАТЫ. На момент манифестации заболевания обе группы были сопоставимы по основным показателям кальций-фосфорного обмена, за исключением уровня бета-кросслапса, который был выше в группе без предоперационной терапии БФ (p=0,0003). Различий по параметрам DXA и 3D-DXA не определялось.</p><p>При сопоставлении групп по абсолютному приросту МПК по результатам DXA в основных отделах скелета и 3D-DXA в бедренной кости значимых различий выявлено не было. Итоговые абсолютные значения параметров 3D-DXA (включая толщину кортикального слоя в бедренной кости в целом и в ее шейке) были выше в группе без терапии, достигая, однако, лишь уровня статистической тенденции.</p><p>Также была проведена оценка динамики МПК внутри групп. У пациентов, получавших БФ, статистически значимый прирост МПК в абсолютных значениях был выявлен только в поясничном отделе позвоночника (р&lt;0,001). По данным 3D-DXA, статистически значимо выше после ПТЭ был только объем минеральной плотности трабекулярной кости бедра в целом (р=0,001).</p><p>В группе без терапии БФ статистически значимые различия по абсолютным показателям МПК в дои послеоперационном периоде наблюдались в поясничном отделе позвоночника (р&lt;0,001), в бедре в целом (р&lt;0,001) и в его шейке (р=0,001). По данным 3D-DXA, статистически значимые различия были выявлены по трем из восьми проанализированных показателей: увеличились объем минеральной плотности трабекулярной кости бедра в целом (р&lt;0,001) и в его шейке (р&lt;0,001), а также объем минеральной плотности кортикальной кости в бедре в целом (р=0,001).</p></sec><sec><title>ЗАКЛЮЧЕНИЕ</title><p>ЗАКЛЮЧЕНИЕ. Метод 3D-DXA позволяет оценить не только МПК, но и микроархитектонику кости, что важно для прогнозирования риска переломов у пациентов с ПГПТ. Исследования показали, что предоперационная терапия БФ может негативно влиять на восстановление МПК после ПТЭ, особенно в кортикальной костной ткани. Для подтверждения этих данных и уточнения влияния БФ на послеоперационное течение ПГПТ необходимы дальнейшие исследования.</p></sec></abstract><trans-abstract xml:lang="en"><sec><title>BACKGROUND</title><p>BACKGROUND: The main treatment for primary hyperparathyroidism (PHPT) is parathyroidectomy (PTE), conservative therapy, including bisphosphonates, can be used for preoperative correction of hypercalcemia, as well as to improve bone tissue condition among individuals for whom surgery should be postponed or cannot be performed due to high perioperative risks. The question of the effect of bisphosphonates on bone tissue after surgery remains open.</p></sec><sec><title>AIM</title><p>AIM: To study the effect of preoperative bisphosphonate therapy on BMD parameters assessed in DXA and 3D-DXA in patients with PHPT one year after radical PTE.</p></sec><sec><title>MATERIALS AND METHODS</title><p>MATERIALS AND METHODS: The study was conducted on the basis of the Department of pathology of the parathyroid glands and disorders of mineral metabolism of "Endocrinology Research Center" state-funded research facility of the Ministry of Health of the Russian Federation. The study included 50 patients (2 men, 48 women), divided into two groups depending on the presence or absence of preoperative bisphosphonate (BF) therapy. The methods of DXA and 3D-DXA using 3D-Shaper Medical software were used to evaluate BMD and bone microarchitectonics. The statistical analysis was performed using the R language and the Statistica v.13 package.</p></sec><sec><title>RESULTS</title><p>RESULTS: At the time of the disease’s manifestation, both groups were comparable in terms of the main indicators of calcium phosphorus metabolism, with the exception of the level of beta-crosslapse, which was higher in the group without preoperative BPh therapy (p&lt;0,001). There were also no differences in the parameters of DXA and 3D-DXA. After surgery, both groups showed a comparable increase in BMD based on the results of DXA in the main parts of the skeleton and 3D-DXA in the femur. Changes at the level of the statistical trend were obtained for the 3D-DXA parameters, the final absolute values of which were slightly higher in the second group, including the thickness of the cortical layer in the femur as a whole and in the neck. When comparing the results of DXA before and after PTE in patients receiving BPh, statistically significant differences in absolute BMD values were obtained only in the lumbar spine (p&lt;0,001).According to 3D-DXA data, statistically significant differences were found only in the volume of mineral density of the trabecular bone of the femur as a whole (p=0,001).</p><p>When analyzing up to — in the second group, statistically significant differences in absolute BMD values were observed in the lumbar region (p&lt;0,001), in the hip as a whole (p&lt;0,001) and in its neck (p=0,001).According to 3D-DXA data, statistically significant differences were found in three of the eight analyzed indicators, the volume of mineral density of the trabecular bone of the femur as a whole and in the neck (p&lt;0,001 for both), as well as the volume of mineral density of the cortical bone in the neck, (p=0,001).</p></sec><sec><title>CONCLUSION</title><p>CONCLUSION: The 3D-DXA method allows us to evaluate not only BMD, but also its microarchitectonics, which is important for predicting the risk of fractures in patients with PHPT. Studies have shown that preoperative BPh therapy can negatively affect the recovery of BMD after PTE, especially in cortical bone tissue. Further studies are needed to confirm these data and clarify the effect of CF on the postoperative course of PHPT.</p></sec></trans-abstract><kwd-group xml:lang="ru"><kwd>первичный гиперпаратиреоз</kwd><kwd>DXA</kwd><kwd>3D-DXA</kwd><kwd>бисфосфонаты</kwd><kwd>паратиреоидэктомия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>primary hyperparathyroidism</kwd><kwd>DXA</kwd><kwd>3D-DXA</kwd><kwd>bisphosphonates</kwd><kwd>parathyroidectomy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017;28(1):1-19. doi: https://doi.org/10.1007/s00198-016-3716-2</mixed-citation><mixed-citation xml:lang="en">Khan AA, Hanley DA, Rizzoli R, Bollerslev J, Young JE, et al. Primary hyperparathyroidism: review and recommendations on evaluation, diagnosis, and management. A Canadian and international consensus. Osteoporos Int. 2017;28(1):1-19. doi: https://doi.org/10.1007/s00198-016-3716-2</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Fraser WD. Hyperparathyroidism. Lancet. 2009;374(9684):145-58. doi: https://doi.org/10.1016/S0140-6736(09)60507-9</mixed-citation><mixed-citation xml:lang="en">Fraser WD. Hyperparathyroidism. Lancet. 2009;374(9684):145-58. doi: https://doi.org/10.1016/S0140-6736(09)60507-9</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Мокрышева Н.Г., Мирная С.С., Добрева Е.А., Маганева И.С., Ковалева Е.В., и др. Первичный гиперпаратиреоз в России по данным регистра. // Проблемы эндокринологии. — 2019. — Т. 65. — №5. — С. 300-310. doi: https://doi.org/10.14341/probl10126</mixed-citation><mixed-citation xml:lang="en">Mokrysheva NG, Mirnaya SS, Dobreva EA, Maganeva IS, Kovaleva EV, et al. Primary hyperparathyroidism in Russia according to the registry. Problems of Endocrinology. 2019;65(5):300-310 (In Russ.). doi: https://doi.org/10.14341/probl10126</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Mokrysheva NG, Eremkina AK, Elfimova AR, Kovaleva EV, Miliutina AP, et al. The Russian registry of primary hyperparathyroidism, latest update. Front Endocrinol (Lausanne). 2023;14:1203437. doi: https://doi.org/10.3389/fendo.2023.1203437</mixed-citation><mixed-citation xml:lang="en">Mokrysheva NG, Eremkina AK, Elfimova AR, Kovaleva EV, Miliutina AP, et al. The Russian registry of primary hyperparathyroidism, latest update. Front Endocrinol (Lausanne). 2023;14:1203437. doi: https://doi.org/10.3389/fendo.2023.1203437</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Дедов И.И., Мельниченко Г.А., Мокрышева Н.Г., Андреева Е.Н., Анциферов М.Б., и др. Проект клинических рекомендаций по диагностике и лечению первичного гиперпаратиреоза у взрослых пациентов. // Эндокринная хирургия. — 2022. — Т. 16. — №4. — С. 5-54. doi: https://doi.org/10.14341/serg12790</mixed-citation><mixed-citation xml:lang="en">Dedov II, Melnichenko GA, Mokrysheva NG, Andreeva EN, Antsiferov MB, et al. Draft of clinical guidelines for the diagnosis and treatment of primary hyperparathyroidism in adult patients. Endocrine Surgery. 2022;16(4):5-54. (In Russ.). doi: https://doi.org/10.14341/serg12790</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032-45. doi: https://doi.org/10.4065/83.9.1032</mixed-citation><mixed-citation xml:lang="en">Drake MT, Clarke BL, Khosla S. Bisphosphonates: mechanism of action and role in clinical practice. Mayo Clin Proc. 2008;83(9):1032-45. doi: https://doi.org/10.4065/83.9.1032</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Orr LE, Zhou H, Zhu CY, Haigh PI, Adams AL, Yeh MW. Skeletal effects of combined medical and surgical management of primary hyperparathyroidism. Surgery. 2020;167(1):144-148. doi: https://doi.org/10.1016/j.surg.2019.04.059</mixed-citation><mixed-citation xml:lang="en">Orr LE, Zhou H, Zhu CY, Haigh PI, Adams AL, Yeh MW. Skeletal effects of combined medical and surgical management of primary hyperparathyroidism. Surgery. 2020;167(1):144-148. doi: https://doi.org/10.1016/j.surg.2019.04.059</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Eller-Vainicher C, Filopanti M, Palmieri S, Ulivieri FM, Morelli V, et al. Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. Eur J Endocrinol. 2013;169(2):155-62. doi: https://doi.org/10.1530/EJE-13-0305</mixed-citation><mixed-citation xml:lang="en">Eller-Vainicher C, Filopanti M, Palmieri S, Ulivieri FM, Morelli V, et al. Bone quality, as measured by trabecular bone score, in patients with primary hyperparathyroidism. Eur J Endocrinol. 2013;169(2):155-62. doi: https://doi.org/10.1530/EJE-13-0305</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Ye Z, Silverberg SJ, Sreekanta A, Tong K, Wang Y, et al. The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Bone Miner Res. 2022;37(11):2351-2372. doi: https://doi.org/10.1002/jbmr.4685</mixed-citation><mixed-citation xml:lang="en">Ye Z, Silverberg SJ, Sreekanta A, Tong K, Wang Y, et al. The Efficacy and Safety of Medical and Surgical Therapy in Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Bone Miner Res. 2022;37(11):2351-2372. doi: https://doi.org/10.1002/jbmr.4685</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Hangge PT, Norain A, Butterfield RJ 3rd, Wasif N, Cronin PA, Stucky CH. Parathyroidectomy in the elderly is beneficial and safe with similar improvements in postoperative bone mineral density. Am J Surg. 2022;224(1 Pt A):147-152. doi: https://doi.org/10.1016/j.amjsurg.2022.04.031</mixed-citation><mixed-citation xml:lang="en">Hangge PT, Norain A, Butterfield RJ 3rd, Wasif N, Cronin PA, Stucky CH. Parathyroidectomy in the elderly is beneficial and safe with similar improvements in postoperative bone mineral density. Am J Surg. 2022;224(1 Pt A):147-152. doi: https://doi.org/10.1016/j.amjsurg.2022.04.031</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Kongsaree N, Thanyajaroen T, Dechates B, Therawit P, Mahikul W, Ngaosuwan K. Skeletal Effect of Parathyroidectomy on Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2024;109(10):e1922-e1935. doi: https://doi.org/10.1210/clinem/dgae326</mixed-citation><mixed-citation xml:lang="en">Kongsaree N, Thanyajaroen T, Dechates B, Therawit P, Mahikul W, Ngaosuwan K. Skeletal Effect of Parathyroidectomy on Patients With Primary Hyperparathyroidism: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab. 2024;109(10):e1922-e1935. doi: https://doi.org/10.1210/clinem/dgae326</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Rajput S, Dutta A, Rajender S, Mithal A, Chattopadhyay N. Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1098841. doi: https://doi.org/10.3389/fendo.2023.1098841</mixed-citation><mixed-citation xml:lang="en">Rajput S, Dutta A, Rajender S, Mithal A, Chattopadhyay N. Efficacy of antiresorptive agents bisphosphonates and denosumab in mitigating hypercalcemia and bone loss in primary hyperparathyroidism: A systematic review and meta-analysis. Front Endocrinol (Lausanne). 2023;14:1098841. doi: https://doi.org/10.3389/fendo.2023.1098841</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Segula D, Nikolova T, Marks E, Ranganath L, Mishra V. Long Term Outcome of Bisphosphonate Therapy in Patients with Primary Hyperparathyroidism. Int J Clin Med. 2014;05(14):829-835. doi: https://doi.org/10.4236/ijcm.2014.514111</mixed-citation><mixed-citation xml:lang="en">Segula D, Nikolova T, Marks E, Ranganath L, Mishra V. Long Term Outcome of Bisphosphonate Therapy in Patients with Primary Hyperparathyroidism. Int J Clin Med. 2014;05(14):829-835. doi: https://doi.org/10.4236/ijcm.2014.514111</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Hsieh S-C, Kibret T, Hamid JS, et al. Bisphosphonates for postmenopausal osteoporosis: a network meta-analysis. Cochrane Database Syst Rev. 2023;2023(9). doi: https://doi.org/10.1002/14651858.CD015008</mixed-citation><mixed-citation xml:lang="en">Hsieh S-C, Kibret T, Hamid JS, et al. Bisphosphonates for postmenopausal osteoporosis: a network meta-analysis. Cochrane Database Syst Rev. 2023;2023(9). doi: https://doi.org/10.1002/14651858.CD015008</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Iwanowska M, Kochman M, Szatko A, Zgliczyński W, Glinicki P. Bone Disease in Primary Hyperparathyroidism-Changes Occurring in Bone Metabolism and New Potential Treatment Strategies. Int J Mol Sci. 2024;25(21):11639. doi: https://doi.org/10.3390/ijms252111639</mixed-citation><mixed-citation xml:lang="en">Iwanowska M, Kochman M, Szatko A, Zgliczyński W, Glinicki P. Bone Disease in Primary Hyperparathyroidism-Changes Occurring in Bone Metabolism and New Potential Treatment Strategies. Int J Mol Sci. 2024;25(21):11639. doi: https://doi.org/10.3390/ijms252111639</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13):1207-15. doi: https://doi.org/10.1056/NEJMoa031975</mixed-citation><mixed-citation xml:lang="en">Black DM, Greenspan SL, Ensrud KE, Palermo L, McGowan JA, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med. 2003;349(13):1207-15. doi: https://doi.org/10.1056/NEJMoa031975</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Choe HJ, Koo BK, Yi KH, Kong SH, Kim JH, Shin CS, Chai JW, Kim SW. Skeletal effects of combined bisphosphonates treatment and parathyroidectomy in osteoporotic patients with primary hyperparathyroidism. J Bone Miner Metab. 2022;40(2):292-300. doi: https://doi.org/10.1007/s00774-021-01279-2</mixed-citation><mixed-citation xml:lang="en">Choe HJ, Koo BK, Yi KH, Kong SH, Kim JH, Shin CS, Chai JW, Kim SW. Skeletal effects of combined bisphosphonates treatment and parathyroidectomy in osteoporotic patients with primary hyperparathyroidism. J Bone Miner Metab. 2022;40(2):292-300. doi: https://doi.org/10.1007/s00774-021-01279-2</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Arboiro-Pinel R, Mahíllo-Fernández I, Díaz-Curiel M. Bone Analysis Using Trabecular Bone Score and Dual-Energy X-Ray Absorptiometry-Based 3-Dimensional Modeling in Postmenopausal Women With Primary Hyperparathyroidism. Endocr Pract. 2022;28(1):83-89. doi: https://doi.org/10.1016/j.eprac.2021.08.006</mixed-citation><mixed-citation xml:lang="en">Arboiro-Pinel R, Mahíllo-Fernández I, Díaz-Curiel M. Bone Analysis Using Trabecular Bone Score and Dual-Energy X-Ray Absorptiometry-Based 3-Dimensional Modeling in Postmenopausal Women With Primary Hyperparathyroidism. Endocr Pract. 2022;28(1):83-89. doi: https://doi.org/10.1016/j.eprac.2021.08.006</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Arboiro-Pinel R, Mahillo-Fernández I, Díaz-Curiel M. Primary Hyperparathyroidism: Assessment of the Effects of Parathyroidectomy Using Dual X-Ray Absorptiometry, Trabecular Bone Score, and Dual X-Ray Absorptiometry-Based Three-Dimensional Modeling. Endocr Pract. 2024;30(4):340-347. doi: https://doi.org/10.1016/j.eprac.2024.01.004</mixed-citation><mixed-citation xml:lang="en">Arboiro-Pinel R, Mahillo-Fernández I, Díaz-Curiel M. Primary Hyperparathyroidism: Assessment of the Effects of Parathyroidectomy Using Dual X-Ray Absorptiometry, Trabecular Bone Score, and Dual X-Ray Absorptiometry-Based Three-Dimensional Modeling. Endocr Pract. 2024;30(4):340-347. doi: https://doi.org/10.1016/j.eprac.2024.01.004</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
